Stifel Nicolaus Initiates Coverage On Karuna Therapeutics with Buy Rating, Announces $126 Price Target

Stifel Nicolaus analyst Paul Matteis initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Buy rating and a $126 price target.

Benzinga · 12/19/2019 11:22

Stifel Nicolaus analyst Paul Matteis initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Buy rating and a $126 price target.